Gentamicin topical - Royer Biomedical

Drug Profile

Gentamicin topical - Royer Biomedical

Alternative Names: AppliGel-G; Gentamicin Sulfate Topical Gel

Latest Information Update: 22 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Royer Biomedical
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Diabetic foot ulcer

Most Recent Events

  • 13 May 2015 Royer Biomedical terminates a phase I/II trial in Diabetic foot ulcer in USA (Topical) (NCT02036528)
  • 01 Jan 2014 Phase-I/II clinical trials in Diabetic foot ulcer in USA (Topical)
  • 25 May 2012 US FDA approves IND application for Royer Biomedical's topical gentamicin in diabetic foot ulcer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top